These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 22749838)

  • 1. Cost-effectiveness of pertussis booster vaccination in the Netherlands.
    Rozenbaum MH; De Cao E; Postma MJ
    Vaccine; 2012 Nov; 30(50):7327-31. PubMed ID: 22749838
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Economic analysis of pertussis illness in the Dutch population: implications for current and future vaccination strategies.
    de Greeff SC; Lugnér AK; van den Heuvel DM; Mooi FR; de Melker HE
    Vaccine; 2009 Mar; 27(13):1932-7. PubMed ID: 19368774
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A critical literature review of health economic evaluations in pertussis booster vaccination.
    Millier A; Aballea S; Annemans L; Toumi M; Quilici S
    Expert Rev Pharmacoecon Outcomes Res; 2012 Feb; 12(1):71-94. PubMed ID: 22280198
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of strategies for use of acellular pertussis vaccine in adolescents and adults: a cost-benefit analysis.
    Purdy KW; Hay JW; Botteman MF; Ward JI
    Clin Infect Dis; 2004 Jul; 39(1):20-8. PubMed ID: 15206048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pertussis in adolescents and adults: should we vaccinate?
    Lee GM; Lebaron C; Murphy TV; Lett S; Schauer S; Lieu TA
    Pediatrics; 2005 Jun; 115(6):1675-84. PubMed ID: 15930232
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of acellular pertussis preschool booster vaccination on disease burden of pertussis in The Netherlands.
    de Greeff SC; Mooi FR; Schellekens JF; de Melker HE
    Pediatr Infect Dis J; 2008 Mar; 27(3):218-23. PubMed ID: 18277916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of a pertussis vaccination programme for Japan considering intergenerational infection.
    Itatani T; Shimizu S; Iwasa M; Ohkusa Y; Hayakawa K
    Vaccine; 2013 Jun; 31(27):2891-7. PubMed ID: 23570987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
    Girard DZ
    Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The impact of pre-school booster vaccination of 4--6-year-old children on pertussis in 0--1-year-old children.
    Hviid A; Stellfeld M; Wohlfahrt J; Andersen PH; Melbye M
    Vaccine; 2006 Feb; 24(9):1401-7. PubMed ID: 16207504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Re: cost-effectiveness of pertussis booster vaccination in the Netherlands.
    O'Mahony JF
    Vaccine; 2012 Nov; 30(50):7141. PubMed ID: 23026686
    [No Abstract]   [Full Text] [Related]  

  • 11. Response on "RE: Cost-effectiveness of pertussis booster vaccination in the Netherlands".
    Rozenbaum MH; Postma MJ
    Vaccine; 2013 Apr; 31(16):2024. PubMed ID: 23246308
    [No Abstract]   [Full Text] [Related]  

  • 12. Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model.
    de Vries R; Kretzschmar M; Schellekens JF; Versteegh FG; Westra TA; Roord JJ; Postma MJ
    PLoS One; 2010 Oct; 5(10):e13392. PubMed ID: 20976213
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economic evaluation of an extended acellular pertussis vaccine programme for adolescents in Ontario, Canada.
    Iskedjian M; Walker JH; Hemels ME
    Vaccine; 2004 Oct; 22(31-32):4215-27. PubMed ID: 15474711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Economic considerations for pertussis booster vaccination in adolescents.
    Hay JW; Ward JI
    Pediatr Infect Dis J; 2005 Jun; 24(6 Suppl):S127-33. PubMed ID: 15931140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pertussis in the Netherlands, is the current vaccination strategy sufficient to reduce disease burden in young infants?
    van der Maas NA; Mooi FR; de Greeff SC; Berbers GA; Spaendonck MA; de Melker HE
    Vaccine; 2013 Sep; 31(41):4541-7. PubMed ID: 23933365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Using computer simulations to compare pertussis vaccination strategies in Australia.
    Hethcote HW; Horby P; McIntyre P
    Vaccine; 2004 Jun; 22(17-18):2181-91. PubMed ID: 15149775
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differences in avidity of IgG antibodies to pertussis toxin after acellular pertussis booster vaccination and natural infection.
    Barkoff AM; Gröndahl-Yli-Hannuksela K; Vuononvirta J; Mertsola J; Kallonen T; He Q
    Vaccine; 2012 Nov; 30(48):6897-902. PubMed ID: 22981763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Conclusions on (cost-)effectiveness of pertussis booster vaccination strategies highly dependent on selections made in evidence review.
    Postma MJ; de Vries R; Roord J
    Vaccine; 2009 Dec; 27(52):7242-3. PubMed ID: 19744583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modelling the impact of extended vaccination strategies on the epidemiology of pertussis.
    Rozenbaum MH; De Vries R; LE HH; Postma MJ
    Epidemiol Infect; 2012 Aug; 140(8):1503-14. PubMed ID: 22115361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of vaccination against pertussis on the incidence of pertussis in The Netherlands, 1996-2003].
    de Greeff SC; Schellekens JF; Mooi FR; de Melker HE
    Ned Tijdschr Geneeskd; 2005 Apr; 149(17):937-43. PubMed ID: 15884408
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.